Parkinsonism in patients with a history of amphetamine exposure
Identifieur interne : 000346 ( Istex/Curation ); précédent : 000345; suivant : 000347Parkinsonism in patients with a history of amphetamine exposure
Auteurs : Chadwick W. Christine [États-Unis] ; Elisabeth R. Garwood [États-Unis] ; Lauren E. Schrock [États-Unis] ; Daniel E. Austin [États-Unis] ; Charles E. Mcculloch [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
Abstract
We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22915
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000346
Links to Exploration step
ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name><affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of California, San Francisco, California</mods:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name><affiliation wicri:level="2"><mods:affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea></affiliation></author><author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name><affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea></affiliation></author><author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name><affiliation wicri:level="2"><mods:affiliation>Colby College, Waterville, Maine</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maine (État)</region></placeName><wicri:cityArea>Colby College, Waterville</wicri:cityArea></affiliation></author><author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name><affiliation wicri:level="2"><mods:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</mods:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22915</idno><idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000346</idno><idno type="wicri:Area/Istex/Curation">000346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name><affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of California, San Francisco, California</mods:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name><affiliation wicri:level="2"><mods:affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea></affiliation></author><author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name><affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea></affiliation></author><author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name><affiliation wicri:level="2"><mods:affiliation>Colby College, Waterville, Maine</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maine (État)</region></placeName><wicri:cityArea>Colby College, Waterville</wicri:cityArea></affiliation></author><author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name><affiliation wicri:level="2"><mods:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</mods:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30">2010-01-30</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno><idno type="DOI">10.1002/mds.22915</idno><idno type="ArticleID">MDS22915</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>neurotoxicant</term><term>neurotoxin</term><term>selective vulnerability</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96
|texte= Parkinsonism in patients with a history of amphetamine exposure
}}
| This area was generated with Dilib version V0.6.23. |  |